Published in Nat Med on April 20, 2015
Prospective Evaluation and Molecular Profiling in People With Gastric Tumors | NCT03027427
Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget (2015) 1.06
Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer (2016) 1.00
Genomic alterations and molecular subtypes of gastric cancers in Asians. Chin J Cancer (2016) 0.93
[Novel pharmaceutical treatment approaches for gastric cancer]. Pathologe (2017) 0.88
Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Med J (2015) 0.87
Oesophageal adenocarcinoma and gastric cancer: should we mind the gap? Nat Rev Cancer (2016) 0.87
Molecular classification and prediction in gastric cancer. Comput Struct Biotechnol J (2015) 0.85
Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Sci Rep (2016) 0.83
A long non-coding RNA signature to improve prognosis prediction of gastric cancer. Mol Cancer (2016) 0.82
Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity. Nat Commun (2016) 0.82
Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol (2016) 0.81
Validation of the Memorial Sloan Kettering Cancer Center nomogram to predict disease-specific survival in a Chinese gastric cancer population receiving postoperative chemoradiotherapy after an R0 resection. Oncotarget (2016) 0.80
Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget (2016) 0.79
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget (2017) 0.79
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. Oncotarget (2017) 0.79
Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways. Cancer Sci (2016) 0.79
Global chemotherapy development for gastric cancer. Gastric Cancer (2016) 0.79
Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol (2016) 0.79
SPARC expression in gastric cancer predicts poor prognosis: Results from a clinical cohort, pooled analysis and GSEA assay. Oncotarget (2016) 0.79
The Origins of Gastric Cancer From Gastric Stem Cells: Lessons From Mouse Models. Cell Mol Gastroenterol Hepatol (2017) 0.78
Gastric Cancer in the Era of Precision Medicine. Cell Mol Gastroenterol Hepatol (2017) 0.78
Incremental diagnostic utility of gastric distension FDG PET/CT. Eur J Nucl Med Mol Imaging (2015) 0.78
A protein and mRNA expression-based classification of gastric cancer. Mod Pathol (2016) 0.78
Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. J Pathol Transl Med (2015) 0.78
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist (2016) 0.78
Mouse models for gastric cancer: Matching models to biological questions. J Gastroenterol Hepatol (2016) 0.77
Noncoding Genomics in Gastric Cancer and the Gastric Precancerous Cascade: Pathogenesis and Biomarkers. Dis Markers (2015) 0.77
Stratification of Digestive Cancers with Different Pathological Features and Survival Outcomes by MicroRNA Expression. Sci Rep (2016) 0.77
Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol (2015) 0.77
The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy. Dig Dis Sci (2017) 0.77
IKKε and TBK1 expression in gastric cancer. Oncotarget (2017) 0.76
Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptor in vitro and in vivo. Oncotarget (2016) 0.76
Ethnicity-related differences in tumor immunity: a new possible explanation for gastric cancer prognostic variability? Transl Gastroenterol Hepatol (2016) 0.76
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis. Sci Rep (2016) 0.76
Immunological battlefield in gastric cancer and role of immunotherapies. World J Gastroenterol (2016) 0.76
Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature. World J Gastroenterol (2016) 0.76
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer (2015) 0.76
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol (2016) 0.76
EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus. BMC Cancer (2016) 0.75
Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas. PLoS One (2016) 0.75
Micronutrients: A double-edged sword in microbial-induced gastric carcinogenesis. Trends Cancer (2015) 0.75
New Biology to New Treatment of Helicobacter pylori-Induced Gastric Cancer. Dig Dis (2016) 0.75
Integrated Analysis Identifies Molecular Signatures and Specific Prognostic Factors for Different Gastric Cancer Subtypes. Transl Oncol (2016) 0.75
Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. Oncotarget (2016) 0.75
A unified model of the hierarchical and stochastic theories of gastric cancer. Br J Cancer (2017) 0.75
Translating genomic profiling to gastrointestinal cancer treatment. Future Oncol (2017) 0.75
Gastric Cancer Genomics: Advances and Future Directions. Cell Mol Gastroenterol Hepatol (2017) 0.75
A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Lett (2016) 0.75
Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget (2017) 0.75
Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers. J Gastrointest Oncol (2016) 0.75
Gastrin and Gastric Cancer. Cell Mol Gastroenterol Hepatol (2017) 0.75
NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. ESMO Open (2016) 0.75
Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2017) 0.75
Increased RhoA Activity Predicts Worse Overall Survival in Patients Undergoing Surgical Resection for Lauren Diffuse-Type Gastric Adenocarcinoma. Ann Surg Oncol (2016) 0.75
The anti-apoptotic and prognostic value of fibroblast growth factor 9 in gastric cancer. Oncotarget (2016) 0.75
Increased gene expression noise in human cancers is correlated with low p53 and immune activities as well as late stage cancer. Oncotarget (2016) 0.75
Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. Oncotarget (2016) 0.75
The era of laparoscopic surgery for gastric cancer: what is the present territory and what will be next? Transl Gastroenterol Hepatol (2016) 0.75
Assessing the clinical utility of genomic expression data across human cancers. Oncotarget (2016) 0.75
MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis. Oncotarget (2016) 0.75
The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. J Gastrointest Oncol (2016) 0.75
Molecular Testing for Gastrointestinal Cancer. J Pathol Transl Med (2017) 0.75
KIF2A Overexpression and Its Association with Clinicopathologic Characteristics and Poor Prognoses in Patients with Gastric Cancer. Dis Markers (2016) 0.75
Molecular mechanisms of gastric cancer initiation and progression by Helicobacter pylori. Curr Opin Infect Dis (2016) 0.75
Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers. Gastroenterol Res Pract (2016) 0.75
Identifying Reproducible Molecular Biomarkers for Gastric Cancer Metastasis with the Aid of Recurrence Information. Sci Rep (2016) 0.75
Chromosomal Instability in Gastric Cancer Biology. Neoplasia (2017) 0.75
Elevated Expression of Calpain-4 Predicts Poor Prognosis in Patients with Gastric Cancer after Gastrectomy. Int J Mol Sci (2016) 0.75
IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis. Mol Cancer (2017) 0.75
A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget (2016) 0.75
Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. PLoS One (2017) 0.75
Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Ann Surg (2016) 0.75
High-risk and low-risk gastric cancer areas in Italy and its association with microsatellite instability. J Cancer Res Clin Oncol (2016) 0.75
Molecular classifications of gastric cancers: Novel insights and possible future applications. World J Gastrointest Oncol (2017) 0.75
Identification of a prognostic 5-Gene expression signature for gastric cancer. J Cancer Res Clin Oncol (2016) 0.75
Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features. Clin Cancer Res (2017) 0.75
miR-551b regulates epithelial-mesenchymal transition and metastasis of gastric cancer by inhibiting ERBB4 expression. Oncotarget (2017) 0.75
How to stomach an epigenetic insult: the gastric cancer epigenome. Nat Rev Gastroenterol Hepatol (2017) 0.75
Development of mesenchymal subtype gene signature for clinical application in gastric cancer. Oncotarget (2017) 0.75
Molecular classification of esophagogastric junction carcinoma correlated with prognosis. Onco Targets Ther (2017) 0.75
Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget (2017) 0.75
Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer (2013) 1.43
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One (2015) 1.15
Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget (2015) 1.06
Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer. PLoS Genet (2015) 1.02
Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget (2015) 1.00
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. PLoS One (2014) 0.97
Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute. Cancer Res Treat (2015) 0.84
The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients. Oncotarget (2016) 0.81
Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors. Oncotarget (2016) 0.81
Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling. Sci Rep (2014) 0.80
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget (2017) 0.79
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion. Oncotarget (2017) 0.79
Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. PLoS One (2013) 0.79
Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. Transl Oncol (2016) 0.78
Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. Oncotarget (2016) 0.77
IKKε and TBK1 expression in gastric cancer. Oncotarget (2017) 0.76
Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors. Oncotarget (2016) 0.76
Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discov (2017) 0.75
Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. Oncotarget (2017) 0.75
Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. Oncotarget (2017) 0.75
MerTK is a novel therapeutic target in gastric cancer. Oncotarget (2015) 0.75
Development of mesenchymal subtype gene signature for clinical application in gastric cancer. Oncotarget (2017) 0.75
Bridging genomics and phenomics of gastric carcinoma. Int J Cancer (2019) 0.75